Every Form 4 that Ernexa Therapeutics Inc. (ERNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics Inc. (ERNA) reported that director James Arthur Bristol received two grants of stock options to purchase common stock. On 2026-08-31, he was granted 8,320 options with a $4.57 exercise price, expiring on 2036-08-31, vesting one-third on the first anniversary and the remainder in 24 monthly installments, subject to continued service. He was also granted 5,083 options at a $4.57 exercise price, expiring on 2036-08-31, in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, with 100% vesting on December 31, 2026, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that director Peter Cicala received two grants of stock options on August 31, 2026. One grant covers 5,943 options with an exercise price of $4.57 per share, vesting one-third on the first anniversary and the rest in 24 monthly installments, expiring August 31, 2036. A second grant covers 5,083 options at $4.57 per share, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vesting 100% on December 31, 2026, also expiring August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that director David Polinsky received a grant of stock options covering 5,083 shares of common stock. The options have an exercise price of $4.57 per share, were granted in lieu of prorated director cash compensation for 2026 under the company’s 2026 Omnibus Equity Incentive Plan, and expire on August 31, 2036. Subject to continued service, 100% of the options vest on December 31, 2026, and Polinsky’s total holdings of this option grant are 5,083 options following the reported transaction.
Ernexa Therapeutics Inc. (ERNA) reported that director William A. Wexler received a grant of stock options for 5,943 shares of common stock. The options have an exercise price of $4.57 per share and expire on August 31, 2036. Following this grant, Wexler holds 5,943 stock options directly. Vesting is time-based: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that director Elena Ratner received a grant of stock options covering 5,944 shares of common stock at an exercise price of $4.57 per share. Subject to continued service, one-third of the option vests on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments through August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that President and CEO Luther Sanjeev received a grant of stock options. The award covers 118,848 options to acquire Ernexa common shares at an exercise price of $4.57 per share, expiring on 2036-08-31. Following this grant, Sanjeev holds 118,848 derivative securities of this type.
The options vest over time: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc. insider and 10% owner Cherington Charles bought 4,000,000 shares of common stock on February 10, 2026, in a follow-on offering pursuant to a prospectus supplement dated February 6, 2026. The combined purchase price per share of common stock and accompanying warrant was $0.50.
At the same time, Cherington Charles acquired 4,000,000 warrants to purchase common stock. These warrants will expire on the earlier of February 10, 2031 or the 180th calendar day following the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.